Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 01 2024
0mins
Should l Buy GILD?
Source: NASDAQ.COM
Overview of SPDR S&P Biotech ETF (XBI): Launched in 2006 and sponsored by State Street Global Advisors, XBI is a passively managed ETF focused on the Healthcare - Biotech sector, with over $7.80 billion in assets and an annual expense ratio of 0.35%. It aims to match the performance of the S&P Biotechnology Select Industry Index.
Performance and Investment Considerations: The ETF has gained approximately 10.80% year-to-date and 35.50% over the past year, while maintaining a diversified portfolio with 141 holdings. Investors are encouraged to review individual holdings and consider other ETFs in the biotech space for broader exposure.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 137.640
Low
105.00
Averages
137.88
High
154.00
Current: 137.640
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly to Acquire Kelonia Therapeutics for Up to $7 Billion
- Acquisition Scale: Eli Lilly announced its acquisition of biotech firm Kelonia Therapeutics for up to $7 billion, with $3.25 billion paid upfront and remaining payments contingent on clinical, regulatory, and commercial milestones, expected to close in the second half of 2026.
- Innovative Treatment Technology: Kelonia is developing in vivo CAR-T technology that reprograms patients' T-cells to attack cancer, offering a more convenient alternative to traditional ex vivo methods, potentially transforming treatment for blood cancers and solid tumors.
- Market Competitive Advantage: Lilly plans to leverage Kelonia's technology to expand into hematology, with Van Naarden emphasizing the appeal of a one-time infusion, which could attract more physicians and break the current limitations of treatments confined to academic medical centers.
- Strategic Transformation Direction: Alongside the Kelonia acquisition, Lilly is diversifying its business through multiple acquisitions, such as Centessa Pharmaceuticals and Orna Therapeutics, gradually shifting from being primarily known for GLP-1 drugs for weight loss to a comprehensive biopharmaceutical company covering more therapeutic areas.
See More
Arcus Biosciences Halts Late-Stage Lung Cancer Trial
- Trial Termination Reason: Arcus Biosciences announced the discontinuation of the STAR-121 trial in collaboration with Gilead Sciences due to futility, indicating poor clinical prospects for the anti-TIGIT therapy domvanalimab, which may impact the company's future R&D direction.
- Clinical Trial Details: The STAR-121 trial evaluated domvanalimab combined with chemotherapy and the anti-PD-1 antibody zimberelimab as a first-line treatment for metastatic non-small cell lung cancer, but the Independent Data Monitoring Committee's recommendation led to its early termination, revealing insufficient efficacy of the therapy.
- Other Study Cessation: The company also announced the halt of the Phase 2 EDGE-Lung study, which assessed domvanalimab with various immunotherapies, further indicating significant challenges in its lung cancer research and potentially affecting its market competitiveness.
- Collaboration Rights Change: Arcus disclosed that effective July 14, 2026, Gilead will no longer hold option rights to certain early-stage pipeline projects due to the non-payment of option continuation fees, which may impact Arcus's cash flow and future collaboration opportunities.
See More
Eli Lilly to Acquire Kelonia Therapeutics for Up to $7 Billion
- Acquisition Scale: Eli Lilly announced its agreement to acquire Kelonia Therapeutics for an upfront payment of $3.25 billion, with a total deal value of up to $7 billion, indicating a strategic move in the oncology sector.
- Technological Innovation: Kelonia is developing in vivo CAR-T technology that reprograms T-cells within patients' bodies to attack cancer, potentially simplifying existing cell therapy processes and enhancing treatment efficiency.
- Market Potential: Lilly's oncology head noted that Kelonia's data is 'nothing short of remarkable,' suggesting that this technology could play a significant role in blood cancer treatment, thereby strengthening Lilly's competitive position in the market.
- Future Outlook: The acquisition is expected to close in the second half of 2026, providing Lilly with an opportunity to expand its product line in hematology and further solidify its leadership in the biopharmaceutical industry.
See More
ARCUS BIOSCIENCES INC - SEC FILING ANNOUNCES DISCONTINUATION OF STAR-121 AND PHASE 2 EDGE-LUNG STUDIES
ARCUS Biosciences Updates: ARCUS Biosciences is continuing its studies on STAR-121 and Phase 2 Edge-Lung, focusing on advancements in their research and development efforts.
SEC Filing: The company has filed with the SEC, indicating ongoing regulatory compliance and transparency in its operations.
See More
Gilead Extends Tender Offer Deadline for Arcellx Acquisition
- Tender Offer Extension: Gilead has extended the deadline for its tender offer to acquire Arcellx until 5 PM ET on April 27, demonstrating the company's flexibility in response to market conditions and aiming to increase shareholder participation.
- Share Tender Status: As of April 16, nearly 18% of Arcellx's outstanding shares have been tendered, up from approximately 7.5% as of March 31, indicating growing shareholder acceptance of the acquisition proposal and enhancing the likelihood of a successful transaction.
- Regulatory Approvals Secured: Gilead has obtained all necessary regulatory approvals, including clearances from Austrian antitrust authorities, which lays a solid foundation for the smooth completion of the deal, ensuring the company can close the acquisition as planned in Q2.
- Acquisition Context: Gilead announced its intention to acquire Arcellx for $7.8 billion in February, having already owned about 12% of its outstanding shares, and the successful acquisition will further solidify its market position in the biopharmaceutical sector.
See More
Gilead Secures Regulatory Approval for Arcellx Acquisition
- Acquisition Approval: Gilead announced it has obtained all necessary regulatory approvals for the acquisition of Arcellx, marking a significant milestone that is expected to enhance Gilead's market position in the biopharmaceutical sector.
- Tender Offer Extension: Gilead has extended the expiration date of its tender offer for Arcellx to April 27, 2026, ensuring that the transaction can be completed smoothly upon satisfying all closing conditions, thereby strengthening its foothold in oncology.
- Shareholder Response: As of April 16, 2026, approximately 10,271,823 shares of Arcellx have been validly tendered, representing about 17.5% of the outstanding shares, indicating positive shareholder response that may support subsequent integration efforts.
- Future Outlook: Gilead aims to achieve over $6 billion in global sales of Arcellx's product by 2030, which, if realized, will trigger a $5 cash payment for holders of the contractual contingent value rights, further boosting investor confidence.
See More
Eli Lilly to Acquire Kelonia Therapeutics for Up to $7 Billion
- Acquisition Scale: Eli Lilly announced its acquisition of biotech firm Kelonia Therapeutics for up to $7 billion, with $3.25 billion paid upfront and remaining payments contingent on clinical, regulatory, and commercial milestones, expected to close in the second half of 2026.
- Innovative Treatment Technology: Kelonia is developing in vivo CAR-T technology that reprograms patients' T-cells to attack cancer, offering a more convenient alternative to traditional ex vivo methods, potentially transforming treatment for blood cancers and solid tumors.
- Market Competitive Advantage: Lilly plans to leverage Kelonia's technology to expand into hematology, with Van Naarden emphasizing the appeal of a one-time infusion, which could attract more physicians and break the current limitations of treatments confined to academic medical centers.
- Strategic Transformation Direction: Alongside the Kelonia acquisition, Lilly is diversifying its business through multiple acquisitions, such as Centessa Pharmaceuticals and Orna Therapeutics, gradually shifting from being primarily known for GLP-1 drugs for weight loss to a comprehensive biopharmaceutical company covering more therapeutic areas.
See More
Arcus Biosciences Halts Late-Stage Lung Cancer Trial
- Trial Termination Reason: Arcus Biosciences announced the discontinuation of the STAR-121 trial in collaboration with Gilead Sciences due to futility, indicating poor clinical prospects for the anti-TIGIT therapy domvanalimab, which may impact the company's future R&D direction.
- Clinical Trial Details: The STAR-121 trial evaluated domvanalimab combined with chemotherapy and the anti-PD-1 antibody zimberelimab as a first-line treatment for metastatic non-small cell lung cancer, but the Independent Data Monitoring Committee's recommendation led to its early termination, revealing insufficient efficacy of the therapy.
- Other Study Cessation: The company also announced the halt of the Phase 2 EDGE-Lung study, which assessed domvanalimab with various immunotherapies, further indicating significant challenges in its lung cancer research and potentially affecting its market competitiveness.
- Collaboration Rights Change: Arcus disclosed that effective July 14, 2026, Gilead will no longer hold option rights to certain early-stage pipeline projects due to the non-payment of option continuation fees, which may impact Arcus's cash flow and future collaboration opportunities.
See More
Eli Lilly to Acquire Kelonia Therapeutics for Up to $7 Billion
- Acquisition Scale: Eli Lilly announced its agreement to acquire Kelonia Therapeutics for an upfront payment of $3.25 billion, with a total deal value of up to $7 billion, indicating a strategic move in the oncology sector.
- Technological Innovation: Kelonia is developing in vivo CAR-T technology that reprograms T-cells within patients' bodies to attack cancer, potentially simplifying existing cell therapy processes and enhancing treatment efficiency.
- Market Potential: Lilly's oncology head noted that Kelonia's data is 'nothing short of remarkable,' suggesting that this technology could play a significant role in blood cancer treatment, thereby strengthening Lilly's competitive position in the market.
- Future Outlook: The acquisition is expected to close in the second half of 2026, providing Lilly with an opportunity to expand its product line in hematology and further solidify its leadership in the biopharmaceutical industry.
See More
ARCUS BIOSCIENCES INC - SEC FILING ANNOUNCES DISCONTINUATION OF STAR-121 AND PHASE 2 EDGE-LUNG STUDIES
ARCUS Biosciences Updates: ARCUS Biosciences is continuing its studies on STAR-121 and Phase 2 Edge-Lung, focusing on advancements in their research and development efforts.
SEC Filing: The company has filed with the SEC, indicating ongoing regulatory compliance and transparency in its operations.
See More
Gilead Extends Tender Offer Deadline for Arcellx Acquisition
- Tender Offer Extension: Gilead has extended the deadline for its tender offer to acquire Arcellx until 5 PM ET on April 27, demonstrating the company's flexibility in response to market conditions and aiming to increase shareholder participation.
- Share Tender Status: As of April 16, nearly 18% of Arcellx's outstanding shares have been tendered, up from approximately 7.5% as of March 31, indicating growing shareholder acceptance of the acquisition proposal and enhancing the likelihood of a successful transaction.
- Regulatory Approvals Secured: Gilead has obtained all necessary regulatory approvals, including clearances from Austrian antitrust authorities, which lays a solid foundation for the smooth completion of the deal, ensuring the company can close the acquisition as planned in Q2.
- Acquisition Context: Gilead announced its intention to acquire Arcellx for $7.8 billion in February, having already owned about 12% of its outstanding shares, and the successful acquisition will further solidify its market position in the biopharmaceutical sector.
See More
Gilead Secures Regulatory Approval for Arcellx Acquisition
- Acquisition Approval: Gilead announced it has obtained all necessary regulatory approvals for the acquisition of Arcellx, marking a significant milestone that is expected to enhance Gilead's market position in the biopharmaceutical sector.
- Tender Offer Extension: Gilead has extended the expiration date of its tender offer for Arcellx to April 27, 2026, ensuring that the transaction can be completed smoothly upon satisfying all closing conditions, thereby strengthening its foothold in oncology.
- Shareholder Response: As of April 16, 2026, approximately 10,271,823 shares of Arcellx have been validly tendered, representing about 17.5% of the outstanding shares, indicating positive shareholder response that may support subsequent integration efforts.
- Future Outlook: Gilead aims to achieve over $6 billion in global sales of Arcellx's product by 2030, which, if realized, will trigger a $5 cash payment for holders of the contractual contingent value rights, further boosting investor confidence.
See More
